"Purines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
| Descriptor ID |
D011687
|
| MeSH Number(s) |
D03.633.100.759
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Purines".
Below are MeSH descriptors whose meaning is more specific than "Purines".
This graph shows the total number of publications written about "Purines" by people in this website by year, and whether "Purines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 2 | 3 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 3 | 4 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 3 | 2 | 5 |
| 2013 | 2 | 3 | 5 |
| 2014 | 3 | 2 | 5 |
| 2015 | 1 | 2 | 3 |
| 2016 | 3 | 0 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 3 | 5 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Purines" by people in Profiles.
-
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro. Biochem Pharmacol. 2024 02; 220:115981.
-
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. Cancer Res Commun. 2023 08; 3(8):1551-1563.
-
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma. Clin Cancer Res. 2022 07 15; 28(14):3002-3010.
-
Physiological and transcription analyses reveal regulatory pathways of 6-benzylaminopurine delaying leaf senescence and maintaining quality in postharvest Chinese flowering cabbage. Food Res Int. 2022 07; 157:111455.
-
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 09; 10(9):888-899.
-
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2021 11 01; 27(21):5760-5770.
-
Hydroxyurea Induces a Stress Response That Alters DNA Replication and Nucleotide Metabolism in Bacillus subtilis. J Bacteriol. 2021 07 08; 203(15):e0017121.
-
Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9. J Med Chem. 2021 07 08; 64(13):9279-9301.
-
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. Invest New Drugs. 2021 10; 39(5):1324-1334.
-
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clin Cancer Res. 2021 08 01; 27(15):4177-4185.